Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

First Drug-Coated Balloon IDE: A Conversation With Lutonix CEO Dennis Wahr

This article was originally published in The Gray Sheet

Executive Summary

Following a four-year effort with FDA, Minneapolis start-up Lutonix recently met its goal to become the first company to gain an investigational device exemption for a drug-coated balloon.

You may also be interested in...



Bard Buys Lutonix For Lead In Race To U.S. Market With Drug-Coated Balloon

Deal worth up to $325 million makes Bard first in line to enter the U.S. market with a drug-coated balloon. Firm anticipates PMA submission for Moxy in 2014.

Lutonix: Back To The Future With Drug-Coated Balloons

Drug-coated balloons were once thought to be an unnecessary innovation because of drug-eluting stents. With DES no longer seen as the panacea for vascular disease, balloons could re-emerge as the next major technology platform, and Lutonix is leading the race to bring them to the US market.

Cook Medical Makes Progress In Peripheral Stent Space

Cook Medical is making advances in the peripheral stent market with the imminent launch of its Formula balloon-expandable renal stent system, and a recent report of two-year data for its PMA-pending Zilver PTX paclitaxel-eluting stent.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT030436

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel